Many more drug combinations are currently being studied and are showing similar rates of efficacy. Though the current studies are small, "it’s hard to argue when you get 100% response rates," Dr. Ghany said.
Although toxicity remains a looming problem – some experimental agents have already been withdrawn on toxicity concerns – Dr. Ghany said he remains optimistic that a safer yet equally or more potent combination will emerge.
Future therapies also are likely to come with shorter treatment times and to be "interferon- and perhaps even ribavirin-free," he said, suggesting it’s not inconceivable that one day soon "we will be treating HCV with a single coformulated pill, perhaps for a duration of only 12 weeks."
Dr. Ghany disclosed no conflicts of interest.